Earnings History Data for ACADIA Pharmaceuticals Inc. (ACAD) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
06-11-2024	AH		ACAD	ACADIA Pharmaceuticals Inc.	2,430	0.20	0.13	-0.40	Acadia Pharma GAAP EPS of $0.20 beats by $0.06, revenue of $250.4M beats by $1.56M [11/6/2024 4:09 PM]	17.23	1.44 (9.09%)	15.90	0.11 (0.70%)	14.15 - 32.59	2,476,515	1,300,000	9,049
Acadia Pharma GAAP EPS of $0.20 beats by $0.06, revenue of $250.4M beats by $1.56M [11/6/2024 4:09 PM] Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million [Nov-05-24 04:05PM] Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview [2024-11-06 04:05PM] Acadia: Q3 Earnings Snapshot [2024-11-06 04:13PM] Acadia Pharmaceuticals (ACAD) Beats Q3 Earnings and Revenue Estimates [2024-11-06 05:15PM] ACADIA Pharmaceuticals Inc (ACAD) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ... [2024-11-07 06:00AM]
06-08-2024	AH		ACAD	ACADIA Pharmaceuticals Inc.	3,140	0.20	0.16	0.01	Acadia Pharma GAAP EPS of $0.20 beats by $0.03, revenue of $241.96M beats by $6.3M [8/6/2024 4:28 PM]	15.19	-3.67 (-19.44%)	15.39	-3.46 (-18.36%)	14.55 - 32.59	6,421,052	2,000,000	69,510
Acadia Pharma GAAP EPS of $0.20 beats by $0.03, revenue of $241.96M beats by $6.3M [8/6/2024 4:28 PM] ACADIA Pharma cut at Morgan Stanley on Daybue miss [8/7/2024 2:22 PM]
08-05-2024	AH		ACAD	ACADIA Pharmaceuticals Inc.	2,800	0.10	0.16	-0.27	Acadia Pharma GAAP EPS of $0.10 beats by $0.05, revenue of $205.83M misses by $2.75M [5/8/2024 4:10 PM]	15.20	-1.93 (-11.30%)	17.00	-0.13 (-0.76%)	15.18 - 33.99	4,644,637	1,590,000	3,432
Acadia Pharma GAAP EPS of $0.10 beats by $0.05, revenue of $205.83M misses by $2.75M [5/8/2024 4:10 PM]
27-02-2024	AH		ACAD	ACADIA Pharmaceuticals Inc.	4,070	0.28	0.32	-0.26	Acadia Pharma GAAP EPS of $0.28 misses by $0.02, revenue of $231.04M beats by $7.24M [2/27/2024 4:11 PM]	23.64	-2.71 (-10.30%)	24.55	-1.81 (-6.87%)	17.71 - 33.99	4,274,046	1,740,000	3,036
Acadia Pharma GAAP EPS of $0.28 misses by $0.02, revenue of $231.04M beats by $7.24M [2/27/2024 4:11 PM]
02-11-2023	AH		ACAD	ACADIA Pharmaceuticals Inc.	3,700	-0.40	-0.43	-0.17	Acadia Pharma GAAP EPS of -$0.40 beats by $0.05, revenue of $211.7M beats by $22.08M [11/2/2023 4:15 PM]	24.09	1.11 (4.81%)	23.81	0.82 (3.57%)	13.73 - 33.99	2,253,713	1,420,000	19,364
Acadia Pharma GAAP EPS of -$0.40 beats by $0.05, revenue of $211.7M beats by $22.08M [11/2/2023 4:15 PM]
02-08-2023	AH		ACAD	ACADIA Pharmaceuticals Inc.	4,760	0.01	-0.12	-0.21	Acadia Pharma GAAP EPS of $0.01 beats by $0.07, revenue of $165.3M beats by $7.46M [8/2/2023 4:15 PM]	27.29	-1.91 (-6.54%)	27.86	-1.34 (-4.59%)	13.73 - 33.99	3,303,660	1,870,000	2,286
Acadia Pharma GAAP EPS of $0.01 beats by $0.07, revenue of $165.3M beats by $7.46M [8/2/2023 4:15 PM]
08-05-2023	AH	4:05 PM ET (May 8)	ACAD	ACADIA Pharmaceuticals Inc.	3,500	-0.27	-0.21	-0.70	ACADIA Pharma GAAP EPS of -$0.27 misses by $0.06, revenue of $118.46M misses by $1.83M [5/8/2023 4:07 PM]	21.43	-0.12 (-0.53%)	21.67	0.12 (0.56%)	12.24 - 22.11	1,470,706	1,270,000	26,428
ACADIA Pharma GAAP EPS of -$0.27 misses by $0.06, revenue of $118.46M misses by $1.83M [5/8/2023 4:07 PM]
27-02-2023	AH	4:05 PM ET (Feb 27)	ACAD	ACADIA Pharmaceuticals Inc.	3,070	-0.26	-0.25	-0.27	ACADIA Pharma GAAP EPS of -$0.26 misses by $0.02, revenue of $136.49M beats by $1.31M [2/27/2023 4:08 PM]	20.72	1.32 (6.81%)	19.40	0.0 (0.00%)	12.24 - 28.06	2,749,815	1,240,000	257,073
ACADIA Pharma GAAP EPS of -$0.26 misses by $0.02, revenue of $136.49M beats by $1.31M [2/27/2023 4:08 PM]
02-11-2022	AH	4:05 PM ET (Nov 2)	ACAD	ACADIA Pharmaceuticals Inc.	2,590	-0.17	-0.18	-0.09	ACADIA Pharma GAAP EPS of -$0.17 beats by $0.02, revenue of $130.71M misses by $8.33M [11/2/2022 4:20 PM]	14.87	-1.06 (-6.69%)	15.50	-0.43 (-2.70%)	12.24 - 28.05	3,305,095	1,340,000	148,238
ACADIA Pharma GAAP EPS of -$0.17 beats by $0.02, revenue of $130.71M misses by $8.33M [11/2/2022 4:20 PM] Acadia Pharmaceuticals sees Q3 mixed bag as it beats on bottom line but misses on top [11/2/2022 5:08 PM] Is a Surprise Coming for Acadia Pharmaceuticals (ACAD) This Earnings Season? [Nov-01-22 10:04AM] Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results [Nov-02-22 04:05PM] Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Misses Revenue Estimates [Nov-02-22 05:35PM] Acadia's (ACAD) Q3 Loss Narrower Than Expected, Revenues Miss [Nov-03-22 12:23PM]
08-08-2022	AH	4:05 PM ET (Aug 8)	ACAD	ACADIA Pharmaceuticals Inc.	2,330	-0.21	-0.25	-0.27	ACADIA Pharma GAAP EPS of -$0.21 beats by $0.05, revenue of $134.56M beats by $4.5M [8/8/2022 4:11 PM]	16.23	-0.39 (-2.35%)	16.35	-0.27 (-1.62%)	12.24 - 28.05	2,566,548	1,830,000	515
ACADIA Pharma GAAP EPS of -$0.21 beats by $0.05, revenue of $134.56M beats by $4.5M [8/8/2022 4:11 PM] FDA Asks For Additional Study For Acadia's Pimavanserin In Alzheimer's-Associated Delusions [Aug-05-22 07:55AM] Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results [Aug-08-22 04:05PM] Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates [Aug-08-22 05:35PM] Acadia's (ACAD) Q2 Earnings & Revenues Surpass Estimates [Aug-09-22 11:06AM]
04-05-2022	AH	4:05 PM ET (May 4)	ACAD	ACADIA Pharmaceuticals	2,973	-0.70	-0.49	0.00	ACADIA Pharma GAAP EPS of -$0.70 misses by $0.13, revenue of $115.5M misses by $6.72M [5/4/2022 4:24 PM]	18.82	-1.07 (-5.38%)	19.50	-0.39 (-1.96%)	15.68 - 28.05	1,009,708	1,740,000	366
ACADIA Pharma GAAP EPS of -$0.70 misses by $0.13, revenue of $115.5M misses by $6.72M [5/4/2022 4:24 PM] ACADIA Pharma net loss widens ~70% but reiterates 2022 guidance [5/4/2022 7:01 PM] Acadia Pharmaceuticals to Present at Upcoming Investor Conferences [May-03-22 04:05PM] Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results [May-04-22 04:05PM] Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates [May-04-22 06:15PM] Acadia (ACAD) Q1 Earnings & Revenues Fall Shy of Estimates [May-05-22 10:06AM]
28-02-2022	AH	4:05 PM ET (Feb 28)	ACAD	ACADIA Pharmaceuticals Inc.	4,150	-0.27	-0.24	-0.42	ACADIA Pharma GAAP EPS of -$0.27 misses by $0.04, revenue of $130.8M misses by $4.64M [2/28/2022 4:10 PM]	25.07	-0.34 (-1.34%)	24.15	-1.26 (-4.96%)	15.68 - 49.91	1,501,458	1,240,000	1,331
ACADIA Pharma GAAP EPS of -$0.27 misses by $0.04, revenue of $130.8M misses by $4.64M [2/28/2022 4:10 PM] Acadia Pharma down 6% after hours after earnings misses [2/28/2022 4:52 PM] Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results [Feb-28-22 04:05PM] Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates [Feb-28-22 05:35PM] Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates [Mar-01-22 09:43AM]
08-11-2021	AH	4:05 PM ET (Nov 8)	ACAD	ACADIA Pharmaceuticals Inc.	3,220	-0.09	-0.27	-0.54	ACADIA Pharma EPS beats by $0.17, beats on revenue [11/8/2021 4:24 PM]	21.62	2.05 (10.48%)	20.74	1.17 (5.98%)	15.68 - 57.46	1,518,729	1,270,000	5,416
ACADIA Pharma EPS beats by $0.17, beats on revenue [11/8/2021 4:24 PM] Acadia's narrows full-year guidance for Nuplazid sales, but shares rise after-hours [11/8/2021 4:24 PM] ACADIA Pharma at a three-month high ahead of key update on dementia therapy [11/9/2021 2:47 PM] Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results [Nov-08-21 04:05PM] Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates [Nov-08-21 05:25PM] ACADIA's (ACAD) Q3 Earnings and Revenues Beat Estimates [Nov-09-21 11:08AM]
04-08-2021	AH	4:10 PM ET (Aug 4)	ACAD	ACADIA Pharmaceuticals Inc.	3,360	-0.27	-0.30	-0.27	ACADIA Pharma EPS beats by $0.03, misses on revenue; FY21 guidance lowered [8/4/2021 4:22 PM]	19.38	-1.67 (-7.93%)	19.86	-1.19 (-5.65%)	19.10 - 57.46	2,619,131	1,410,000	23,816
ACADIA Pharma EPS beats by $0.03, misses on revenue; FY21 guidance lowered [8/4/2021 4:22 PM] ACADIA Pharma slides after 2021 guidance lagged expectations [8/4/2021 5:03 PM] ACADIA: The Streets Gaze Turns to FDA Meetings Outcome on DRP Treatment [Aug-03-21 07:30PM] Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Misses Revenue Estimates [Aug-04-21 05:25PM] ACADIA (ACAD) Q2 Earnings Beat, Revenues Miss Estimates [Aug-05-21 12:53PM] Acadia Pharmaceuticals to Present at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021 [Aug-05-21 04:05PM]
05-05-2021	AH	4:05 PM ET (May 5)	ACAD	ACADIA Pharmaceuticals Inc.	3,290	-0.42	-0.53	-0.57	ACADIA Pharma EPS beats by $0.12, misses on revenue [5/5/2021 4:15 PM]	20.94	1.54 (7.94%)	19.50	0.10 (0.52%)	19.20 - 58.72	2,298,534	1,680,000	3,614
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of RIDE, ROOT and ACAD [May-04-21 03:40PM] SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [May-04-21 03:00PM] The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of DOX, CAN and ACAD [May-04-21 02:45PM] HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ACAD, FGEN, RMO Investors on Securities Class Actions and Application Deadlines, Encourages Investors with Losses to Contact the Firm [May-04-21 02:00PM] CLASS ACTION UPDATE for BLU, NEPT and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders [May-04-21 11:30AM] The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Acadia Pharmaceuticals Inc. (ACAD) Investors [May-04-21 11:15AM] LFMD, FUV & ACAD Reminders: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm [May-04-21 11:00AM] Acadia Pharmaceuticals to Present at Upcoming Investor Conferences [May-04-21 09:00AM] SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Acadia Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - ACAD [May-05-21 11:42AM] CLASS ACTION UPDATE for RMO, CS and ACAD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders [May-05-21 12:10PM] INVESTOR ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm [May-05-21 02:00PM] Lawsuits Filed Against ROOT, EBON and ACAD - Jakubowitz Law Pursues Shareholders Claims [May-05-21 02:30PM] ACADIA Pharmaceuticals, Inc. to Host Earnings Call [May-05-21 02:45PM] Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results [May-05-21 04:10PM] ACAD DEADLINE: HAGENS BERMAN, National Trial Attorneys, Alerts Acadia Pharmaceuticals (ACAD) Investors to Securities Class Action, Advises Investors with Losses to Contact Its Attorneys Now [May-05-21 05:07PM] SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Acadia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 18, 2021 - ACAD [May-05-21 06:39PM] Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intrusion, LifeMD, Romeo Power, and Acadia Pharmaceuticals and Encourages Investors to Contact the Firm [May-05-21 10:14PM] ACAD ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 18, 2021 in the Class Action Filed on Behalf of Acadia Pharmaceuticals Inc. Limited Shareholders [May-06-21 06:18AM] ACADIA (ACAD) Q1 Earnings Beat, Revenues Fall Shy of Estimates [May-06-21 07:17AM] Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Acadia Pharmaceuticals Inc. (ACAD) [May-06-21 11:31AM] The Gross Law Firm Announces Class Actions on Behalf of Shareholders of CYDY, NEPT and ACAD [May-06-21 12:30PM] Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates [May-05-21 06:05PM] The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ACAD, CCIV and PTON [May-06-21 01:45PM] HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Advises ACAD, FGEN, RMO Investors with Losses to Contact the Firm, Updates on Securities Class Actions and Application Deadlines [May-06-21 04:50PM]
24-02-2021	AH	4:05 PM ET (Feb 24)	ACAD	ACADIA Pharmaceuticals Inc.	7,980	-0.42	-0.48	-0.34	ACADIA Pharma EPS beats by $0.05, misses on revenue [2/24/2021 4:07 PM]	47.31	-1.38 (-2.83%)	49.50	0.81 (1.66%)	30.02 - 58.72	1,005,605	787,548	1,161
ACADIA Pharma EPS beats by $0.05, misses on revenue [2/24/2021 4:07 PM] Acadia Q4 topline jumps 23%, provides FY forecast [2/24/2021 5:05 PM] ROCE Insights For ACADIA Pharmaceuticals [Feb-25-21 09:17AM] ACADIA Pharmaceuticals, Inc. to Host Earnings Call [Feb-24-21 02:30PM]
04-11-2020	AH	4:05 PM ET (Nov 4)	ACAD	ACADIA Pharmaceuticals Inc.	7,250	-0.54	-0.38	-0.29	ACADIA Pharma EPS misses by $0.18, beats on revenue [11/4/2020 4:08 PM]	48.56	-0.57 (-1.16%)	46.88	-2.25 (-4.58%)	30.02 - 58.72	1,427,921	1,336,501	6,182

05-08-2020	AH	4:05 PM ET (Aug 5)	ACAD	ACADIA Pharmaceuticals Inc.	6,480	-0.27	-0.44	-0.38	ACADIA Pharma EPS beats by $0.18, beats on revenue [8/5/2020 4:07 PM]	43.52	0.65 (1.52%)	43.00	0.13 (0.30%)	23.77 - 58.72	1,317,205	1,436,097	4,545